RESEARCH ARTICLE

Ac2-26 Mimetic Peptide of Annexin A1 Inhibits Local and Systemic Inflammatory Processes Induced by Bothrops moojeni Venom and the Lys-49 Phospholipase A2 in a Rat Model

Bruna Stuqui1*, Marina de Paula-Silva1☯, Carla Patrícia Carlos1, Anwar Ullah2, Raghuvir Krishnaswamy Arni2, Cristiane Damas Gil3, Sonia Maria Oliani1*

1 Laboratory of Immunomorphology, Department of Biology, São Paulo State University (UNESP), São José do Rio Preto, São Paulo, Brazil, 2 Multiuser Center for Biomolecular Innovation, Department of Physics, São Paulo State University (UNESP), São José do Rio Preto, São Paulo, Brazil, 3 Department of Morphology and Genetics, São Paulo Federal University (UNIFESP), São Paulo, Brazil

☯ These authors contributed equally to this work.

* smoliani@ibilce.unesp.br

Abstract

Annexin A1 (AnxA1) is an endogenous glucocorticoid regulated protein that modulates anti-inflammatory process and its therapeutic potential has recently been recognized in a range of systemic inflammatory disorders. The effect of the N-terminal peptide Ac2-26 of AnxA1 on the toxic activities of Bothrops moojeni crude venom (CV) and its myotoxin II (MjTX-II) were evaluated using a peritonitis rat model. Peritonitis was induced by the intraperitoneal injection of either CV or MjTX-II, a Lys-49 phospholipase A2. Fifteen minutes after the injection, the rats were treated with either Ac2-26 or PBS. Four hours later, the CV and MjTX-II-induced peritonitis were characterized by neutrophilia (in the peritoneal exudate, blood and mesentery) and increased number of mesenteric degranulated mast cells and macrophages. At 24 hours post-injection, the local inflammatory response was attenuated in the CV-induced peritonitis while the MjTX-II group exhibited neutrophilia (in the peritoneal exudate, blood and mesentery) and increased number of mesenteric degranulated mast cells and macrophages. At 24 hours post-injection, the local inflammatory response was attenuated in the CV-induced peritonitis while the MjTX-II group exhibited neutrophilia (in the peritoneal exudate, blood and mesentery) and increased number of mesenteric degranulated mast cells and macrophages. Ac2-26 treatment prevented the influx of neutrophils in MjTX-II-induced peritonitis and diminished the proportion of mesenteric degranulated mast cells and macrophages in CV-induced peritonitis. Additionally, CV and MjTX-II promoted increased levels of IL-1β and IL-6 in the peritoneal exudates which were significantly reduced after Ac2-26 treatment. At 4 and 24 hours, the endogenous expression of AnxA1 was upregulated in the mesenteric neutrophils (CV and MjTX-II groups) and mast cells (CV group). In the kidneys, CV and MjTX-II administrations were associated with an increased number of macrophages and morphological alterations in the juxtamedullary nephrons in proximal and distal tubules. Ac2-26 promoted significant recovery of the juxtamedullary structures, decreased the number of macrophages and diminished the AnxA1 in epithelial cells from distal tubules and renal capsules. Our results show that Ac2-26 treatment significantly attenuates local and systemic inflammatory processes and indicate this peptide as a potential target for the development of new therapeutic strategies for the snakebite envenomation treatment.
Introduction

Ophidic accidents constitute a serious and neglected public health problem in tropical countries [1]. In Brazil, there were 25,302 cases of ophidic envenomation reported in 2013, primarily caused by snakes belonging to the genus *Bothrops*, [2] of which 0.5% were lethal.

*Bothrops* snake venoms induce a pathophysiological condition characterized by local and systemic effects [3, 4]. The local effects include pain, edema, local hemorrhage, inflammation and bruising [5–7] and generally result in tissue necrosis [3]. The systemic effects result in clotting, cardiovascular and renal alterations, hypovolemic shock and bleeding at sites distant from the bite [4]. Some of the primary components responsible for the pathophysiological effects of bothropic venoms are the phospholipases A$_2$ (PLA$_2$s), which are a family of lipolytic enzymes that play key roles in several cellular processes by regulating the release of arachidonic acid and lysophospholipids from cell membrane phospholipids [8]. PLA$_2$s can be classified into two groups: i) the catalytically active enzymes, such as Asp49-PLA$_2$s and ii) the catalytically inactive PLA$_2$ variants (principally Lys49- and Arg49-PLA$_2$s) [9].

The site of action of the venoms is marked by proteolysis, acute inflammation, clotting and bleeding. During the inflammatory response, macrophages release mediators, endothelial cells become activated and leukocytes transmigrate into the tissues [10]. The inflammatory response is modulated by the action of anti-inflammatory mediators, such as annexin A1 (AnxA1), a 37 kDa calcium and phospholipid binding protein that is an inhibitor of glucocorticoid-induced eicosanoid synthesis and PLA$_2$ [11]. In addition, AnxA1 induces shedding of L-selectin in tissues which inhibits the adhesion, migration and recruitment of neutrophils to the inflamed site and accelerates neutrophil apoptosis [12, 13]. These anti-inflammatory effects of AnxA1 represent a key role in the modulation of the inflammatory response.

In spite of the evidence indicating that AnxA1 modulates pathologic processes related to inflammation, the use of either anti-inflammatory or other associated drugs along with anti-venom is not widespread in Brazil [14]. The conventional antivenom treatment is inefficient in the prevention of local effects; however, some anti-inflammatory drugs have been shown to significantly reduce the tissue damage provoked by bothropic envenomation [15]. Therefore, investigations of complementary therapies are warranted to understand the inflammatory cellular mechanisms and develop novel, alternative therapeutic strategies.

The aim of this study was to analyse the effects of Ac2-26 post-treatment on the local and systemic effects of *B. moojeni* crude venom (CV) and the purified catalytically inactive Lys-49 PLA$_2$ (MjTX-II) [16, 17]. Thus, we studied the action of these molecules on the recruitment of neutrophils, and the activation of macrophages and mast cells in the mesentery. The histopathology and the transmigration of macrophages were analyzed in the kidneys and used as indicators of systemic effects. Considering the important role of AnxA1 in the inflammatory response, the endogenous expression of this protein in the mesenteric inflammatory cells as well as in the renal structures was also evaluated.

Materials and Methods

Ethics statement and animals

Male Wistar rats weighing 150–200 g were randomly distributed into nine groups (n = 5/group) and were housed with a 12 h light–dark cycle and allowed food and water *ad libitum*. The experiments were performed in strict accordance with the Brazilian laws of protection and
this study was approved by the Committee on the Ethics of Animal Experiments of the São José do Rio Preto Medical School, São Paulo, Brazil (Permit Number: 5314/2009).

The crude lyophilized *B. moojeni* venom (CV; 250 mg) was purchased from the Sanmaru Serpentarium (SANMARU Ltda., Taquaral, São Paulo, Brazil) and the MjTX-II was purified following the published procedure [16].

**Model of Inflammation**

The experimental peritonitis was induced by intraperitoneal (i.p.) injection of 100 µg CV or 100 µg of MjTX-II, diluted in 0.5 mL PBS. MjTX-II constitutes approximately 7% of the crude venom of *B. moojeni* [16]. Control rats were injected with 0.5 mL PBS (i.p.). The animals were anesthetized with isoflurane (1%) before the experimental treatments were performed and were sacrificed either 4 or 24 hours later by an overdose of ketamine and xylazine anesthetic (100 and 20 mg/kg; i. p.).

**Pharmacological treatment with N-terminal peptide of AnxA1 (Ac2-26)**

The rats were treated with the N-terminal peptide Ac2-26 (Ac-AMVSEFLKQAWFIEE-QEYVQTVK; Invitrogen, USA), 1 mg/kg (i.p.), 15 minutes after peritonitis induction by either CV or MjTX-II to determine the therapeutic efficacy of the AnxA1.

**Histopathological analyses**

The kidney and mesenteric samples were fixed in 4% buffered formalin for 24 hours, dehydrated ingraded ethanol and embedded in paraffin for immunohistochemical and histopathological analysis.

**Kidneys:** Sections of 4 µm were stained with hematoxylin–eosin and analyzed using a high-power objective (40X) on an Axioskop 2-Mot Plus Zeiss microscope (Carl Zeiss, Jena, Germany).

**Mesentery:** The mesenteric fragments were also fixed in 4% paraformaldehyde and 0.5% glutaraldehyde, sodium cacodylate buffer 0.1 M (pH 7.4) for 24 h at 4°C, dehydrated by graded methanol, and embedded in LR Gold resin (London Resin; Reading, Berkshire, U.K.) for the quantitative analysis of the neutrophils and mast cells. The mesenteric infiltrating cells were evaluated in 1 µm tissue sections embedded in LRGold and counted using a high-power objective (40x) on an Axioskop 2-Mot Plus Zeiss microscope (Carl Zeiss, Jena, Germany). The average number of neutrophils and mast cells was calculated and recorded. The values were reported as the mean ±SEM of the number of cells/mm². Mast cells were also analyzed morphologically and classified as either intact or degranulated after staining with toluidine blue 0.5% (Taab Laboratories, UK).

**Quantitative analysis of blood and peritoneal neutrophils**

The peritoneal exudates and the blood obtained by cardiac puncture were diluted 1:10 in Turk’s solution (0.1% crystal violet in 3% acetic acid) for neutrophil quantification in a Neubauer chamber (Laboroptik; Friedrichsdorf, Hessen, Germany). The values are reported as the mean ± SEM of the number of cells x 10³/mL.

**Immunohistochemistry analysis**

The mesenteric and kidney paraffin-embedded sections (4 µm) were submitted to an antigen-retrieval step using a citrate buffer (pH 6.0) at 96°C for 30 min. The endogenous peroxide activity was blocked with 3% hydrogen peroxide for 30 min followed by an incubation overnight at
4°C with either polyclonal rabbit anti-AnxA1 (Zymed Laboratories, Cambridge, UK) or monoclonal mouse anti-rabbit anti-ED-1 (Serotec, Oxford, UK) (1:2000 and 1:500, respectively, in 1% BSA diluted in PBS) antibodies. Some sections were incubated with 1% BSA instead of the primary antibody to provide a negative control for the reaction. After washing, the sections were incubated with a secondary biotinylated Ab (Dako, Cambridge, UK). Positive staining was detected using a peroxidase-conjugated streptavidin complex and the color was developed using the DAB substrate (Dako, Carpinteria, USA). Finally, the sections were washed in distilled water, counterstained with hematoxylin, and mounted. The analysis was conducted on an Axioskop 2-Mot Plus Microscope (Carl Zeiss, Jena, GR), using the AxioVision software for densitometric and quantitative analysis.

The densitometric analysis were conducted to determine the amount of AnxA1 in the mesenteric neutrophils and mast cells (objective x63) and the juxtamedullary nephrons (objective x20) on an arbitrary scale from 0 to 255, and the data were expressed as the mean ± (±SEM). The quantification of macrophages is reported as the mean ± SEM of the number of cells/mm² in mesentery and the cells/20 fields (using a high-power objective x40) in the renal juxtamedullar region.

Cytokine levels
Aliquots of peritoneal exudate were centrifuged at 400 x g for 10 min and tested for transforming growth factor IL-1β and IL-6 by ELISA. The cytokine concentrations were measured using a commercially available immunoassay kit (R&D Systems, Minneapolis, MN, USA) and the levels were estimated according to the manufacturer’s instructions. All experiments were performed in duplicate and the data were expressed as the means ± SEM.

Statistical analysis
The data were analyzed using GraphPad software version 4.00. Statistical differences between means were determined by analysis of variance followed, if significant, by the Bonferroni test. A probability value less than 0.05 was considered to be significant.

Results
Post-treatment with the Ac2-26 peptide downregulates the inflammatory response induced by the administration of CV and MjTX-II
Initially, we examined the inflammatory response profile resulting from CV- and MjTX-II-induced peritonitis. In the initial phase of peritonitis (4 hours) CV markedly increased the influx of blood neutrophils in comparison to the control groups. MjTX-II administration produced a similar effect only at 24 hours (Fig 1A). Consistent with these results, the peritoneal exudates from animals treated with CV (4 hours) and MjTX-II (4 and 24 hours) also exhibited a significant increase in the number of neutrophils, (Fig 1B) when compared with the control animals.

Ac2-26 post-treatment efficiently reduced the blood neutrophil influx provoked by CV and MjTX-II-induced peritonitis (Fig 1A) at 4 and 24 hours, respectively. This effect was associated with diminished peritoneal neutrophil recruitment in the MjTX-II group at 24 hours, but no significant effect was observed in the CV group (Fig 1B).

In addition, the peritoneal exudates displayed a marked increase in the IL-1β and IL-6 levels 4 hours after CV and MjTX-II administration (Table 1). As expected, the Ac2-26 treatment efficiently reduced the levels of both proinflammatory cytokine levels, although only IL-6 was significantly different between untreated and Ac2-26-treated CV group (Table 1). Similarly, an inflammatory
response was detected in the mesenteries 4 hours after CV and MjTX-II injection and was characterized by elevated numbers of extravasated neutrophils and mast cell activation compared to the control animals (Fig 2A–2C, 2G and 2H; Table 2). Additionally, CV triggered a significant increase in the number of macrophages in the mesentery (Table 2) whereas no change was observed in the number of macrophages following MjTX-II administration. At 24 h of peritonitis, no alterations were observed in the inflammatory cell counts (Fig 2D, 2G and 2H; Table 2).

Post-pharmacological treatment with Ac2-26 was effective in inhibiting the influx of neutrophils into the mesentery in the peritonitis induced by MjTX-II, but not by CV (Fig 2E–2H). The anti-inflammatory effects of the peptide were associated with mast cell activation in CV and MjTX-II-peritonitis, and macrophage recruitment to the mesentery that presented diminished cell counts in the CV-induced peritonitis (Table 2).

Endogenous AnxA1 expression is modulated in inflammatory cells by the administration of CV and MjTX-II

After 4 and 24 hours of either CV or MjTX-II administration, we observed extravasated neutrophils and intense AnxA1 immunoreactivity compared to the control group (Fig 3A–3C, 3E

| Time (h) | Treatment | IL-1 (pg/mL) | IL-6 (pg/mL) |
|---------|-----------|--------------|--------------|
| 0 (control) |  | 82 ± 24 | ND |
| 4 / CV |  | 612 ± 186 * | 1199 ± 383 *** |
| 24 / CV |  | 44.5 ± 7 | ND |
| 4 / CV + Ac2-26 |  | 293 ± 54 | 278 ± 64 ## |
| 24 / CV + Ac2-26 |  | 72.5 ± 16 | ND |
| 4 / MjTX-II |  | 1086 ± 295.5 *** | 959 ± 245 *** |
| 24 / MjTX-II |  | 58 ± 14 | ND |
| 4 / MjTX-II + Ac2-26 |  | 570 ± 122 | 456.5 ± 90 |
| 24 / MjTX-II + Ac2-26 |  | 37 ± 16 | ND |

Peritonitis was induced in rats by i.p. injection of CV (100 μg) or MjTX-II (100 μg) in 0.5 mL of PBS. Control group received i.p. only PBS. Another set of animals were treated i.p. with 1 mg/kg of Ac2-26 peptide after 15 minutes of CV or MjTX-II injection. Peritoneal exudate was collected 4 and 24 hours after peritonitis inductions and cytokine dosages were performed by ELISA, as described in Methods. Values are expressed as the mean ± SEM of cytokine levels (n = 5 rats/group). ND < 31.25 pg/mL (not detected).

* P < 0.05 and *** P < 0.001 vs control
## P < 0.01 vs CV 4 h.

**Table 1. Effect of Ac2-26 treatment on proinflammatory cytokine secretion.**
Fig 2. Effect of Ac2-26 treatment on the mesenteric inflammation induced by CV and MjTX-II. Intact mast cells (arrows) in the control mesentery (A). Inflamed mesentery of CV—(B) and MjTX-II-induced peritonitis (C-D) with extravasated neutrophils in the tissue (arrowheads) as observed at 4 and 24 h. Reduced neutrophil influx (arrowheads) after Ac2-26 post-treatment at 4 (E) and 24 h (F) of MjTX-II-induced peritonitis. Vessels (V). Stain: Toluidine blue. Scale bars: 10 μm. Quantitative analysis of extravasated neutrophils in the
and 3F). We did not detected immunostaining in the cells used as a negative control (Fig 3D). These histological observations were confirmed by densitometric analysis of AnxA1 (Fig 3G and 3H).

Similar results were obtained for mesenteric mast cells in CV-induced peritonitis, and we detected high endogenous levels of AnxA1 in these cells at 4 and 24 hours (Fig 4A and 4B). Following MjTX-II administration, the AnxA1 expression was significantly decreased in mast cells (Fig 4C). Fig 4D presents the section incubated in the absence of the primary antibody to provide a negative control of the reaction. The histological sections, sequential to those obtained for immunohistochemistry (Fig 4E–4H), were stained with toluidine blue (Fig 3F) to confirm that the immunostained cells were mast cells. The densitometric analysis of AnxA1 expression on mast cells corroborates our histological findings (Fig 4I and 4J).

Ac2-26 restores the renal damage induced by the administration of CV and MjTX-II

After the characterization of the local effects of CV and MjTX-II administration, we evaluated the systemic damage. For this evaluation, the kidneys were examined 4 and 24 hours after CV and MjTX-II–induced peritonitis. As expected, morphological alterations were detected specially in the proximal (PT) and distal (DT) tubules of juxtamedullary nephrons in the treated group compared to the control group (Fig 5). At 4 hours, the CV group exhibited renal tubular epithelial cells with conspicuous and pyknotic nucleus (Fig 5B) and, at 24 hours, some epithelial cells from the proximal tubules lacked nuclei (Fig 5C), which indicates a process of necrosis and karyolysis. Additionally, hyaline casts, produced by detachment of epithelial cells, were detected in the renal tubular lumens in both CV and MjTX-II groups and at both time points

Table 2. Quantitative analysis of degranulated mast cell and macrophages into mesentery.

| Time (h)/ Treatment | Degranulated mast cell (% of cells/mm²) | Macrophages (cells/mm²) |
|---------------------|--------------------------------------|-------------------------|
| 0 (control)         | 25 ± 15                              | 45.3 ± 13.3             |
| 4 / CV              | 64.5 ± 12.2**                        | 133 ± 10***             |
| 24 / CV             | 46 ± 13.8                            | 60.3 ± 2.8              |
| 4 / CV + Ac2-26     | 33.1 ± 11*                           | 29.5 ± 4.9***           |
| 24 / CV + Ac2-26    | 25.4 ± 12.3                          | 46.7 ± 3               |
| 4 / MjTX-II         | 62.2 ± 11,7**                        | 56 ± 10.6              |
| 24 / MjTX-II        | 48 ± 6.4                             | 30.6 ± 7.3             |
| 4 / MjTX-II + Ac2-26| 39.6 ± 12                            | 61 ± 10.1              |
| 24 / MjTX-II + Ac2-26| 31.4 ± 17                           | 39.8 ± 12.7            |

Peritonitis was induced in rats by i.p. injection of CV (100 μg) or MjTX-II (100 μg) in 0.5 mL of PBS. Control group received i.p. only PBS. Another set of animals were treated i.p. with 1 mg/kg of Ac2-26 peptide after 15 minutes of CV or MjTX-II injection. Mesentery was collected after 4 and 24 hours after peritonitis induction and cellular counts performed as described in Methods. Values are expressed as the mean ± SEM of the number of cells per mm² (n = 5 rats/group).

** P < 0.01 and
*** P < 0.001 vs control
*P < 0.05 and
**P < 0.001 vs CV 4 h.
Post pharmacological treatment with Ac2-26 promoted significant recovery of juxtamedullary structures in the CV (Fig 5F) and MjTX-II groups. In addition to the morphological alterations, we observed that the administration of MjTX-II caused a marked influx of macrophages into the renal glomerulus and interstitium (Fig 6) at 24 hours, as detected by anti-ED-1 antibodies. The treatment with Ac2-26 peptide efficiently decreased the numbers of macrophages in both renal compartments in the MjTX-II group at 24 hours (Fig 6C–6E), but not in the CV group, suggesting an inhibitory regulation of monocyte recruitment into the tissue.

CV and MjTX-II upregulates AnxA1 expression in renal tissues

Endogenous AnxA1 immunostaining was analyzed in the juxtamedullary nephrons in all experimental groups and its expression was detected in epithelial cells, especially from the glomerular capsule and distal convoluted tubules (Fig 7). CV administration induced increased levels of AnxA1 in the epithelial cells from both compartments (distal tubules and glomerular capsules) after 4 and 24 h, compared to the control group (Fig 7A–7C). Similar observations were made in the epithelial cells from distal tubules of MjTX-II group at both time points (Fig 7D and 7E), but no alterations were detected in the renal capsule. Absence of immunoreactivity was observed in the negative control (Fig 7F). Post-treatment with Ac2-26 peptide decreased immunostaining for endogenous AnxA1 in epithelial cells from the distal tubules and renal capsule 4 and 24 h after CV and MjTX-II administration (Fig 7G–7J). The densitometric analysis confirmed our histological findings (Fig 7K–7N).
Discussion

The anti-inflammatory effects of AnxA1 and its mimetic peptide Ac2-26 have been reported in several in vivo models of acute, chronic and systemic inflammation [18–21]. However, few studies have monitored their pharmacological actions in local and systemic inflammatory processes caused by ophidic accidents. We examined the protective effect of Ac2-26 post pharmacological treatment on local and systemic inflammatory processes induced by intraperitoneal injection of B. moojeni crude venom (CV) and its Lys-49 phospholipase A2 (MjTX-II) in rats.

CV-induced peritonitis caused an intense inflammatory response at 4 hours characterized by increased numbers of blood, peritoneal and mesenteric neutrophils, which was absent at 24 hours. Our findings are in agreement with rodent models of carrageenan and zymosan peritonitis [11, 18] which are characterized by the high number of neutrophils that are circulating and transmigrating to the peritoneal cavity in the first 4–6 hours. Previous investigations with Bothrops venoms also observed leukocyte infiltration, predominantly composed of neutrophils, at the site of injury in the first hours after venom application [22, 23]. Additionally, B. asper venom stimulates the expression of adhesion molecules, such as L-selectin, LFA-1, ICAM-1, PECAM-1 and CD-18 on neutrophils and endothelial cells which facilitates their transmigration into the injured tissue [24].

MjTX-II administration also induced neutrophilia at 4 (blood, peritoneal exudates and mesentery) and 24 hours (peritoneal exudates and blood), demonstrating that the bothropic venom myotoxin participates in neutrophil transmigration into the tissue. These findings corroborate the data that in the gastrocnemius muscle of animals that received B. moojeni PLA2, leukocyte infiltration and drastic myonecrosis was observed after 24 hours [25]. We have no direct evidence that MjTX-II can stimulate the bone marrow; however, the rapid increase of

Fig 4. Light micrographs of rat mesenteries showing AnxA1 immunoreactivity in the mast cells. AnxA1-positive mast cells in the control group (A). After 24 hours, the administration of CV and MjTX-II was associated with intense (B) and low (C) AnxA1 immunoreactivity in mast cells (arrows), respectively. Negative control of reaction (D). Counterstain: hematoxylin. Stained adjacent histological sections with 0.5% toluidine blue confirms that the indicated cells are mast cells (arrows; E-H). Scale bars: 5 μm. Densitometric analysis of mesenteric mast cells immunostained for AnxA1 in CV (I) and MjTX-II (J) groups. The values (arbitrary units) are expressed as the mean ± SEM of sections analyzed from 5 rats /group. ***P < 0.001 vs control.

doi:10.1371/journal.pone.0130803.g004
inflammatory cells in blood and peritoneal fluids that we observed may indicate that this PLA2 
stimulates bone marrow proliferation. This effect has been suggested by models of peritonitis 
induced by a metalloproteinase from *B. asper* [26] and a toxin from *B. jararaca* [27], in which 
the production of myeloblasts, myelocytes and granulocytes precursor cells was increased.
The increased numbers of degranulated mast cells in the mesentery 4 hours after induced 
peritonitis are also supported by other studies using *B. jararaca* and *Protobothrops mucrosqua-
matus* crude venoms, as well as PLAs2 isolated from *B. jararacussu* and *B. atrox* [28–31]. The 
importance of mast cells in neutrophil migration was demonstrated in peritonitis and uveitis 
models, where mast cells were selectively depleted using 48/80 compound [32, 33]. These 
experiments indicated a reduction in neutrophil influx into the peritoneal cavity after 4 hours 
of zymosan-induced peritonitis [32] and to the aqueous humor after 24 hours of lipopolysac-
charide-induced uveitis [33] compared to animals whose cells were not depleted. The potent 
mediators released by mast cell degranulation, especially prostaglandin 2 (PGD2), histamine 
and leukotrienes, are responsible for the local inflammatory process and edema induced by *B. moojeni* venom [34]. The amines released by mast cells and phospholipids hydrolysis may act 
as possible mechanisms to the edema induction by *B. pirajai* MjTX-II [35]. On the other hand, 
mast cell activation by snake venoms leads to the release of carboxypeptidases A and other pro-
teases, that can degrade the venom components [36].

The involvement of PLA2 in edema has been described in several studies, but this mecha-
nisms remains unclear [37, 38]. Both the catalytic activity [25] and the positively charged con-
tent [35, 39] present in the majority of secreted PLA2 have been described in several reports.

---

Fig 5. Histopathological analysis of kidneys after CV- and MjTX-II-induced peritonitis. (A) Normal 
histological condition of proximal (PT) and distal convoluted tubules (DT) in the renal control. (B-E) CV- and 
MjTX-II PLAs2-induced peritonitis provoked renal damage characterized by the presence of pyknotic nuclei 
(arrowheads), karyolysis (white arrow) and hyaline casts (asterisks) in proximal tubules. (F) Ac2-26 peptide 
restores the normal morphological aspect of juxtamedullary structures. Stain: Hematoxylin-Eosin. Scale bars: 
20 μm.

doi:10.1371/journal.pone.0130803.g005
...and are considered to be important for its inflammatory activity. A possible mechanism to explain the different pharmacological effects of the catalytically inactive PLA2s from snake venoms, such as Lys-49 (MjTX-II), is based on the hydrophobic cationic stretch located in the C-terminal region, which permits the inactive PLA2s to embed in and disorganize the membrane [30, 35, 39–41].

Ac2-26 post-treatment markedly reduced the proportion of degranulated mast cells in the mesenteries of treated rats at 4 hours in both models of peritonitis (CV and MjTX-II) as well as the circulating neutrophils after 4 hours of CV (~81%) and after 24 hours of MjTX-II (~63%). For MjTX-II-induced peritonitis, the peptide treatment was more effective in modulating neutrophil recruitment, as shown by the significant reduction of mesenteric neutrophils after 4 hours (~65%), as well as that of circulating (~63%) and peritoneal cells (~65%) at 24 hours, compared to untreated rats. Additionally, the anti-inflammatory effect of Ac2-26 was also associated with the inhibition of proinflammatory cytokine release, IL-1β and IL-6, 4 hours after the administration of both CV and MjTX-II. Our findings support the anti-inflammatory roles of AnxA1 and its mimetic peptide described in the literature under different inflammatory conditions and associated with neutrophil transmigration [20, 42–45] cytokine levels [20, 46], and mast cell activation [42, 47].

Mast cells are promising candidates to be activated by PLA2s from snake venoms, and, therefore, to release vasoactive inflammatory mediators such as histamine [30, 35, 48, 49]. Compounds rich in cationic charges such as Lys-49 MjTX-II activate rat mast cells in vitro [50, 51] and in vivo [52]. Because plasma membranes from mast cells contain fixed anionic sites
Fig 7. Analysis of AnxA1 expression in the juxtamedullary renal structures. AnxA1 immunostaining was detected in the epithelial cells under all of the experimental conditions (A, C, E, G, I), concentrated in the glomerular capsule (arrows) and distal convoluted tubules (asterisks). Ac2-26 post-treatment decreased the immunostaining for endogenous AnxA1 in the distal tubules and glomerular capsule (D, F, H, J) 4 and 24 h after CV- and MjTX-II-induced peritonitis. Negative control of the reaction (B). Counterstain: hematoxylin. Scale bars: 20 μm. Densitometric analysis of the epithelial cells from distal convoluted tubules (K-L) and glomerular capsule (M-N) immunostained for AnxA1. Values (arbitrary units) are expressed as the mean ± SEM of sections analyzed from 5 rats/group. **P < 0.01 and ***P < 0.001 vs control; ###P < 0.001 vs CV groups; §§P < 0.01 and §§§P < 0.001 vs MjTX-II groups at the corresponding experimental time. doi:10.1371/journal.pone.0130803.g007
constituted mainly of sulfated glycosaminoglycans [48, 53], it is proposed that mast cell activation by the cations of MjTX-II takes place by electrostatic interactions with these cell surface anionic sites [30]. Thus, Ac2-26 contributed to the reduction of mast cell activation by MjTX-II, thereby inhibiting the inflammatory cascade.

In addition to mast cells and neutrophils, macrophages are important cells with vasoactive and inflammatory properties and their study is necessary to understand the progressive tissue damage. CV- and MjTX-II-induced peritonitis promoted increased numbers of mesenteric and renal macrophages that were abrogated by pharmacological treatment with Ac2-26, demonstrating its anti-inflammatory role in moderating of tissue damage. In our laboratory, we found that Ac2-26 treatment reduced the migration of macrophages to kidney, and attenuated the hemodynamic changes and tubular injury in experimental models of cyclosporine-[43] and tacrolimus-induced nephrotoxicity [45].

Activated macrophages produce several vasoactive substances that can damage renal tissue via reactive oxygen species, nitric oxide, enzymes, and pro-inflammatory cytokines. These effects are related to mechanisms involved in CsA nephrotoxicity and we could not exclude a role for macrophages in CV and MjTX-II nephrotoxicity [54].

Renal consequences demonstrate the ability of the venom to affect remote organs, with functional alterations becoming evident only after 24 hours, coinciding with the resolution phase of local and initial systemic effects. It has been demonstrated that bothropic venom is capable of inducing renal alterations by both direct and indirect mechanisms caused by cytotoxicity and ischemia, respectively [55].

The histopathological damage observed in the kidneys suggests that acute kidney injury (AKI) [56] is responsible for the majority deaths in those that survive the initial accident symptoms [57]. This direct action has significant relevance to the features of tubular injury in AKI [58]. Tubular cells are bound together by basolateral junctions that are composed of cytoskeletal elements, and the disorganization of these junctions affects the integrity of the structure. Myotoxins present in Bothrops venoms destabilize the membranes of the epithelial tubular cells [59] by a mechanism which diminishes cellular permeability with respect to ions and macromolecules, resulting in calcium influx. The uncontrolled calcium entering the tubular cells activates calcium-dependent proteases and endogenous phospholipases, which compromise cytoskeletal organization. This process is considered the main cause of the casts that we observed in juxtamedullary proximal tubules after CV and MjTX-II administration, resulting in the loss of important junction and anchoring functions, leading to the detachment of these cells [60, 61]. The effects of these alterations are identical to the effects that are triggered by CV myotoxins, suggesting that the MjTX-II could be responsible for the direct action of B. moojeni CV [59, 62]. Among the induced injuries caused by CV, we also observed tubular cells with pyknotic and missing nucleous (karyolysis) that are characteristic of necrotic process. Nuclear pyknosis occurs also after renal ischemia and reperfusion [19], suggesting that the triggering of necrosis could be associated with ischemia, as an indirect effect of CV, following the induction of hemodynamic disturbances [63].

It is important to define the biological actions of Ac2-26 treatment in this inflammatory model; immunohistochemical analysis confirmed the expression of AnxA1 in the mesenteric mast cells and neutrophils as described earlier [64–66]. The administration of CV and MjTX-II triggered an increase in endogenous AnxA1 levels in neutrophils at 4 and 24 hours. In mast cells, AnxA1 expression was differently modulated by CV and MjTX-II. CV and MjTX-II were associated with high and low levels of the protein, respectively. Moreover, mast cells contain increased levels of endogenous AnxA1 in response to glucocorticoid treatment [64], chronic inflammation [67], and tumourigenesis [68]. Taken together, our results confirm that neutrophils and mast cells represent important sources of AnxA1 in the tissues and thereby
contribute to the regulation of inflammatory responses triggered by CV and MjTX-II-induced peritonitis.

In the renal tissue, we provide evidence that AnxA1 expression increase in juxtamedullary distal tubules and glomeruli after CV and MjTX-II administration, while post-treatment with the peptide reduced the endogenous levels of AnxA1. These results were confirmed in a model of renal ischemia/reperfusion injury [19]. Similarly, recent results from our research group demonstrated that the immunosuppressives CsA [43] and Tacrolimus [45] induce an increase in renal AnxA1 expression to protect cell function and structure [69]. In addition, renal tubular cells subject to high calcium levels in vitro also upregulate endogenous AnxA1, which plays a pivotal role in enhancing calcium oxalate monohydrate-cell binding and the inhibition of cell proliferation and migration [70].

The findings of this study are outlined in Fig 8 and, taken together, the data provides evidence that the N-terminal peptide of AnxA1, Ac2-26, significantly attenuated the local and systemic inflammatory processes. We propose that these experimental findings may have a
significant impact on and relevance for the development of new therapeutic strategies for envenomation.

Author Contributions
Conceived and designed the experiments: CDG SMO. Performed the experiments: BS MPS. Analyzed the data: BS MPS CPC CDG SMO. Contributed reagents/materials/analysis tools: SMO RKA. Wrote the paper: BS MPS CDG SMO RKA. Contributed with the crude venom and Lys-49 phospholipase A2 purification: AU RKA.

References
1. Soerensen B. Principais serpentes de interesse médico. Reconhecimento, Distribuição geográfica no Continente Americano. In: Atheneu EL, editor. Animais Peçonhentos: Reconhecimento, Clínica e Tratamento. São Paulo/Rio de Janeiro1990. p. 138.
2. Saúde Md. Acidentes por animais peçonhentos–serpentes2011 October, 2011. Available from: http://portal.saude.gov.br/portal/saude/profissional/area.cfm?id_area=1539.
3. Gutiérrez JM, Lomonte B. Local tissue damage induced by Bothrops snake venoms. A review. Mem Inst Butantan. 1989; 51:211–23.
4. Kamiguti A, Hay C, Theakston R, Zuzel M. Insights into the mechanism of haemorrhage caused by snake venom metalloproteinases. Toxicon. 1996; 34(6):627–42. PMID: 8817809.
5. Mebs D, Owmby C. Myotoxic components of snake venoms: their biochemical and biological activities. Pharmacol Ther. 1990; 48(2):223–36. PMID: 2293240.
6. Gutiérrez JM, Lomonte B. Local pathological effects induced by Bothrops snake venom. Mem Inst Butantan. 1995; 33:1405–74.
7. Voronov E, Apte RN, Soler S. The systemic inflammatory response syndrome related to the release of cytokines following severe envenomation. J Venom Anim Toxins. 1999; 5:5–33.
8. Moreira V, Gutiérrez JM, Soares AM, Zamunér SR, Purgatto E, Teixeira CeF. Secretory phospholipases A(2) isolated from Bothrops asper and from Crotalus durissus terrificus snake venoms induce distinct mechanisms for biosynthesis of prostaglandins E2 and D2 and expression of cyclooxygenases. Toxicon. 2008; 52(3):428–39. doi: 10.1016/j.toxicon.2008.06.012 PMID: 18619987.
9. dos Santos Ji, Cintra-Francischinelli M, Borges RJ, Fernandes CA, Pizzo P, Cintra AC, et al. Structural, functional, and bioinformatics studies reveal a new snake venom homologue phospholipase A(2) class. Proteins. 2011; 79(1):61–78. Epub 2010/09/30. doi: 10.1002/prot.22858 PMID: 20878713.
10. Nourshargh S, Marelli-Berg F. Transmigration through venular walls: a key regulator of leukocyte phenotype and function. Trends Immunol. 2005; 26(3):157–65. PMID: 15745858.
11. Oliani S, Paul-Clark M, Christian H, Flower R, Perretti M. Neutrophil interaction with inflamed postcapillary venule endothelium alters annexin 1 expression. Am J Pathol. 2001; 158(2):603–15. PMID: 11159197.
12. Perretti M, Flower R. Annexin 1 and the biology of the neutrophil. J Leukoc Biol. 2004; 76(1):25–9. PMID: 14966195.
13. Solito E, Kamal A, Russo-Marie F, Buckingham J, Marullo S, Perretti M. A novel calcium-dependent proapoptotic effect of annexin 1 on human neutrophils. FASEB J. 2003; 17(11):1544–6. PMID: 12824302.
14. Manual de diagnóstico e tratamento de acidentes por animais peçonhentos [Internet]. Fundação Nacional de Saúde. 1999.
15. Araujo SD, de Souza A, Nunes FP, Gonçalves LR. Effect of dexamethasone associated with serum therapy on treatment of Bothrops jararaca venom-induced paw edema in mice. Inflamm Res. 2007; 56(10):409–13. Epub 2007/11/21. doi: 10.1007/s00011-007-7054-x PMID: 18026697.
16. Soares AM, Rodrigues VM, Homsi-Brandeburgo MI, Toyama MH, Lombardi FR, Arni RK, et al. A rapid procedure for the isolation of the Lys-49 myotoxin II from Bothrops moojeni (caissaca) venom: biochemical characterization, crystallization, myotoxic and edematogenic activity. Toxicon. 1998; 36(3):503–14. Epub 1998/06/24. doi: S0041-0101(97)00133-5 [pii]. PMID: 9637370.
17. Watanabe L, Soares AM, Ward RJ, Fontes MR, Arni RK. Structural insights for fatty acid binding in a Lys49-phospholipase A2: crystal structure of myotoxin II from Bothrops moojeni complexed with stearic acid. Biochimie. 2005; 87(2):161–7. Epub 2005/03/12. doi: S0006-3007(05)00041-7 [pii] doi: 10.1016/j.bochimie.2004.11.005 PMID: 15760708.
18. Gastardelo TS, Damazo AS, Dalli J, Flower RJ, Perretti M, Oliani SM. Functional and ultrastructural analysis of annexin A1 and its receptor in extravasating neutrophils during acute inflammation. Am J Pathol. 2009; 174(1):177–83. Epub 2008/12/20. doi: 10.2353/ajpath.2009.080342 S0002-9440(10)61276-X [pii]. PMID: 19095957; PubMed Central PMCID: PMC2631330.

19. Facio FN Jr, Sena AA, Araujo LP, Mendes GE, Castro I, Luz MA, et al. Annexin 1 mimetic peptide protects against renal ischemia/reperfusion injury in rats. J Mol Med (Berl). 2011; 89(1):51–63. Epub 2010/10/19. doi: 10.1007/s00109-010-0684-4 PMID: 20953576.

20. Girol AP, Mimura KK, Drewes CC, Bolonheis SM, Solito E, Farsky SH, et al. Anti-inflammatory mechanisms of the annexin A1 protein and its mimetic peptide Ac2-26 in models of ocular inflammation in vivo and in vitro. J Immunol. 2013; 190(11):5689–701. Epub 2013/05/07. doi: 10.4049/jimmunol.1202030 jimmunol.201202030 [pii]. PMID: 23645879.

21. Leoni G, Neumann PA, Kamaly N, Quiros M, Nishio H, Jones HR, et al. Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair. J Clin Invest. 2015; 125(3):1215–27. Epub 2015/02/11. doi: 10.1172/JCI76693 76693 [pii]. PMID: 25664854.

22. Carneiro AS, Ribeiro OG, Cabrera WH, Vorraro F, De Franco M, Ibañez OM, et al. Bothrops jararaca venom (BjV) induces differential leukocyte accumulation in mice genetically selected for acute inflammatory reaction: the role of host genetic background on expression of adhesion molecules and release of endogenous mediators. Toxicon. 2008; 52(5):619–701. Epub 2008/07/31. doi: 10.1016/j.toxicon.2008.07.012 PMID: 18723041.

23. Gutiérrez JM, Chaves F, Cerdas L. Inflammatory infiltrate in skeletal muscle injected with Bothrops asper venom. Rev Biol Trop. 1986; 34(2):209–14. PMID: 22134335.

24. Zamuner SR, Zuliani JP, Fernandes CM, Gutiérrez JM, de Fatima Pereira Teixeira C. Inflammation induced by Bothrops asper venom: release of proinflammatory cytokines and eicosanoids, and role of adhesion molecules in leukocyte infiltration. Toxicon. 2005; 46(7):806–13. Epub 2005/10/04. doi: S0041-0101(05)00310-7 [pii]. PMID: 16198389.

25. Santos-Filho NA, Silveira LB, Oliveira CZ, Bernardes CP, Menaldo DL, Fuly AL, et al. A new acidic protein from Bothrops moojeni snake venom. Toxicon. 2008; 52(8):908–17. Epub 2008/06/20. doi: 10.1016/j.toxicon.2008.06.020 PMID: 18929590.

26. Fernandes CM, Zamuner SR, Zuliani JP, Rucavado A, Gutiérrez JM, Teixeira Cde F. Inflammatory effects of BaP1 a metalloproteinase isolated from Bothrops moojeni snake venom: leukocyte recruitment and release of cytokines. Toxicon. 2006; 47(5):549–59. Epub 2006/03/15. doi: S0041-0101(06)00030-4 [pii]. PMID: 16529786.

27. Maria DA, Vassao RC, Ruiz IR. Haematopoietic effects induced in mice by the snake venom toxin jararhagin. Toxicon. 2003; 42(6):579–85. Epub 2003/11/07. doi: S004101010300237X [pii]. PMID: 14602113.

28. Ito NM, Noronha AM, Bohm GM. Carrageenan-induced acute inflammatory response in chicks. Res Vet Sci. 1989; 46(2):192–5. Epub 1989/03/01. PMID: 2704884.

29. Kanaoka Y, Urade Y. Hematopoietic prostaglandin D synthase. Prostaglandins Leukot Essent Fatty Acids. 2003; 69(2–3):163–7. Epub 2003/08/05. doi: S0952327803000772 [pii]. PMID: 12895599.

30. Landucci EC, Castro RC, Pereira MF, Cintra AC, Giglio JR, Marangoni S, et al. Mast cell degranulation induced by two phospholipase A2 homologues: dissociation between enzymatic and biological activities. Eur J Pharmacol. 1998; 343(2–3):257–63. Epub 1998/05/07. doi: S0014-2999(97)01546-X [pii]. PMID: 9570475.

31. Kanashiro MM, de Cassia MER, Petretski JH, Prates MV, Alves EW, Machado OL, et al. Biochemical and biological properties of phospholipases A(2) from Bothrops atrox snake venom. Biochem Pharmacol. 2002; 64(7):1179–86. Epub 2002/09/18. doi: S0006295202012881 [pii]. PMID: 1234622.

32. Ajuébor MN, Das AM, Virág L, Flower RJ, Szabó C, Perretti M. Role of resident peritoneal macrophages and mast cells in chemokine production and neutrophil migration in acute inflammation: evidence for an inhibitory loop involving endogenous IL-10. J Immunol. 1999; 162(3):1685–91. PMID: 9973430.

33. da Silva PS, Girol AP, Oliani SM. Mast cells modulate the inflammatory process in endotoxin-induced uveitis. Mol Vis. 2011; 17:1310–9. doi: 147 [pii]. PMID: 21633711; PubMed Central PMCID: PMCPMC3103740.

34. Galvao Nascimento N, Sampaio MC, Amaral Olivo R, Teixeira C. Contribution of mast cells to the oedema induced by Bothrops moojeni snake venom and a pharmacological assessment of the inflammatory mediators involved. Toxicon. 2010; 55(2–3):343–52. Epub 2009/08/26. doi: 10.1016/j.toxicon.2009.08.009 S0041-0101(09)00429-2 [pii]. PMID: 19703484.

35. Landucci EC, de Castro RC, Toyama M, Giglio JR, Marangoni S, De Nucci G, et al. Inflammatory oedema induced by the lys-49 phospholipase A(2) homologue piratoxin-i in the rat and rabbit. Effect of
polyanions and p-bromophenacyl bromide. Biochem Pharmacol. 2000; 59(10):1289–94. Epub 2000/03/29. doi: 10.1006/bphc.2000.1186. PMID: 10736429.

36. Metz M, Piliponsky AM, Chen CC, Lammel V, Abrink M, Pejler G, et al. Mast cells can enhance resistance to snake and honeybee venoms. Science. 2006; 313(5786):526–30. Epub 2006/07/29. doi: 10.1126/science.1128877 PMID: 16873664.

37. Kini RM, Evans HJ. A model to explain the pharmacological effects of snake venom phospholipases A2. Toxicon. 1989; 27(6):613–35. PMID: 2665186.

38. Murakami M, Kudo I. Phospholipase A2. J Biochem. 2002; 131(3):285–92. PMID: 11872155.

39. Lomonte B, Moreno E, Tarkowski A, Hanson LA, Maccarana M. Neutralizing interaction between heparin and myotoxin II, a lysine 49 phospholipase A2 from Bothrops asper snake venom: Identification of a heparin-binding and cytolytic toxin region by the use of synthetic peptides and molecular modeling. J Biol Chem. 1994; 269(47):29867–73. Epub 1994/11/25. PMID: 7961981.

40. Lomonte B, Rangel J. Snake venom Lys49 myotoxins: From phospholipases A(2) to non-enzymatic membrane disruptors. Toxicon. 2012; 60(4):520–30. Epub 2012/07/12. doi: 10.1016/j.toxicon.2012.02.007 S0041-0101(12)00046-3 [pii]. PMID: 22781132.

41. Lomonte B, Moreno E, Tarkowski A, Hanson LA, Maccarana M. Neutralizing interaction between heparins and myotoxin II, a lysine 49 phospholipase A2 from Bothrops asper snake venom. Identification of a heparin-binding and cytolytic toxin region by the use of synthetic peptides and molecular modeling. J Biol Chem. 1994; 269(47):29867–73. Epub 1994/11/25. PMID: 7961981.

42. Damazo AS, Yona S, Flower RJ, Perretti M, Oliani SM. Annexin A1 protein attenuates PLA2-induced oedema in rat skin and histamine release. Agents Actions. 1992; 36(3):1416–22. Epub 2005/03/24. doi: jpet.104.080473 [pii] doi:10.1124/jpet.104.080473 PMID: 15784654.

43. Araujo LP, Truzzi RR, Mendes GE, Luz MA, Burdmann EA, Oliani SM. Annexin A1 protein attenuates cyclosporine-induced renal hemodynamics changes and macrophage infiltration in rats. Inflamm Res. 2012; 61(3):189–96. Epub 2011/11/22. doi: 10.1007/s00011-011-0400-z PMID: 22101490.

44. Guido BC, Zanatelli M, Tavares-de-Lima W, Oliani SM, Damazo AS. Annexin-A1 peptide down-regulates the leucocyte recruitment and up-regulates interleukin-10 release into lung after intestinal ischemia-reperfusion in mice. J Inflamm (Lond). 2013; 10(1):10. Epub 2013/03/19. doi: 10.1186/1476-9255-10-10 1476-9255-10-10 [pii]. PMID: 23497133; PubMed Central PMCID: PMC3608250.

45. Araujo LP, Truzzi RR, Mendes GE, Luz MA, Burdmann EA, Oliani SM. Interaction of the anti-inflammatory annexin A1 protein and tacrolimus immunosuppressant in the renal function of rats. Am J Nephrol. 2010; 31(6):527–33. Epub 2010/05/21. doi: 10.1159/000309756 000309756 [pii]. PMID: 20484890.

46. Yang YH, Aeberli D, Dacumos A, Xue JR, Morand EF. Annexin-1 regulates macrophage IL-6 and TNF via glucocorticoid-induced leucine zipper. J Immunol. 2009; 183(2):1435–45. Epub 2009/06/26. doi: 10.4049/jimmunol.0804000 jimmunol.0804000 [pii]. PMID: 19553536.

47. Bandeira-Melo C, Bonavita AG, Diaz BL, PM ES, Carvalho VF, Jose PJ, et al. A novel effect for annexin 1-derived peptide ac2-26: reduction of allergic inflammation in the rat. J Pharmacol Exp Ther. 2005; 313(3):1416–22. Epub 2005/03/24. doi: jpet.104.080473 [pii] doi:10.1124/jpet.104.080473 PMID: 15784654.

48. Murakami M, Nakatani Y, Kudo I. Type II secretory phospholipase A2 associated with cell surfaces via C-terminal heparin-binding lysine residues augments stimulus-initiated delayed prostaglandin generation. J Biol Chem. 1996; 271(47):30041–63. Epub 1992/07/01. PMID: 1382379.

49. Moreno JJ, Ferrer X, Ortega E, Carganico G. PLA2-induced oedema in rat skin and histamine release in rat mast cells. Evidence for involvement of lyso phospholipids in the mechanism of action. Agents Actions. 1992; 36(4–5):258–63. Epub 1999/07/01. PMID: 1382379.

50. Coleman JW, Holgate ST, Church MK, Godfrey RC. Immunoglobulin E decapetide-induced 5-hydroxytryptamine release from rat peritoneal mast cells. Comparison with corticotropin-(1–24)-peptide, polyarginine, polylysine and antigen. Biochem J. 1981; 198(3):615–9. Epub 1981/09/15. PMID: 7326027; PubMed Central PMCID: PMC1163309.

51. Ennis M, Pearce FL, Weston PM. Some studies on the release of histamine from mast cells stimulated with polylysine. Br J Pharmacol. 1980; 70(2):329–34. Epub 1980/10/01. PMID: 6159031; PubMed Central PMCID: PMC2044337.

52. Antunes E, Mariano M, Cirirgo G, Levi S, de Nucci G. Pharmacological characterization of polycation-induced rat hind-paw oedema. Br J Pharmacol. 1990; 101(4):986–90. Epub 1990/12/01. PMID: 2085720; PubMed Central PMCID: PMC1977853.

53. Schwartz LB. Mast cells: function and contents. Curr Opin Immunol. 1994; 6(1):91–7. Epub 1994/02/01. PMID: 8172685.
54. Carlos CP, Mendes GE, Miquelin AR, Luz MA, da Silva CG, van Rooijen N, et al. Macrophage depletion attenuates chronic cyclosporine A nephrotoxicity. Transplantation. 2010; 89(11):1362–70. Epub 2010/06/11. PMID:20535850.

55. de Castro I, Burdmann EA, Seguro AC, Yu L. Bothrops venom induces direct renal tubular injury: role for lipid peroxidation and prevention by antivenom. Toxicon. 2004; 43(7):833–9. Epub 2004/07/31. doi: 10.1016/j.toxicon.2004.03.015 S0041-0101(04)001199 [pii]. PMID:15284018.

56. Kumar VA, A.K.; Fausto N.; Aster J.C.. Robbins & Cotran—Patologia: bases patológicas das doenças. 8ª ed ed. Rio de Janeiro: Elsevier; 2010.

57. Rodrigues Sgrignolli L, Florido Mendes GE, Carlos CP, Burdmann EA. Acute kidney injury caused by Bothrops snake venom. Nephron Clin Pract. 2011; 119(2):c131–6; discussion c7. Epub 2011/07/16. doi: 10.1159/000324228 000324228 [pii]. PMID:21757950.

58. Boer-Lima PA, Gontijo JA, da Cruz-Hofling MA. Histologic and functional renal alterations caused by Bothrops moojeni snake venom in rats. Am J Trop Med Hyg. 1999; 61(5):698–706. Epub 1999/12/10. PMID:10586897.

59. Gutierrez JM, Lomonte B. Phospholipase A2 myotoxins from Bothrops snake venoms. Toxicon. 1995; 33(11):1405–24. PMID:8744981.

60. Molitoris BA. Ischemia-induced loss of epithelial polarity: potential role of the actin cytoskeleton. Am J Physiol. 1991; 260(6 Pt 2):F769–78. Epub 1991/06/01. PMID:2058700.

61. Paller MS. Lateral mobility of Na,K-ATPase and membrane lipids in renal cells. Importance of cytoskeletal integrity. J Membr Biol. 1994; 142(1):127–35. Epub 1994/10/01. PMID:7773449.

62. Assakura MT, Reichl AP, Asperti MC, Mandelbaum FR. Isolation of the major proteolytic enzyme from the venom of the snake Bothrops moojeni (caissaca). Toxicon. 1985; 23(4):691–706. Epub 1985/01/01. PMID:3933145.

63. Collares-Buzato CB, de Paula Le Sueur L, da Cruz-Hofling MA. Impairment of the cell-to-matrix adhesion and cytotoxicity induced by Bothrops moojeni snake venom in cultured renal tubular epithelia. Toxicol Appl Pharmacol. 2002; 181(2):124–32. Epub 2002/06/08. doi: 10.1006/taap.2002.9404 S0041-008X(02)99404-4 [pii]. PMID:12051996.

64. Sena AA, Provazzi PJ, Fernandes AM, Cury PM, Rahal P, Oliani SM. Spatial expression of two anti-inflammatory mediators, annexin 1 and galectin-1, in nasal polypsis. Clin Exp Allergy. 2006; 36(10):1260–7. doi: CEA2570 [pii] doi:10.1111/j.1365-2222.2006.02570.x PMID:17014434.

65. Polli-Lopes AC, Estofollete CF, Oliani SM, Zucoloto S, Cunha FQ, Gil CD. Myenteric denervation in gastric carcinogenesis: differential modulation of nitric oxide and annexin-A1. Int J Clin Exp Pathol. 2013; 6(1):13–23. PMID:23236538; PubMed Central PMCID: PMC3515986.

66. Gil C, La M, Perretti M, Oliani S. Interaction of human neutrophils with endothelial cells regulates the expression of endogenous proteins annexin 1, galectin-1 and galectin-3. Cell Biol Int. 2006; 30(4):338–44. PMID:16530434.

67. Oliani SM, Ciocca GA, Pimentel TA, Damazo AS, Gibbs L, Perretti M. Fluctuation of annexin-A1 positive mast cells in chronic granulomatous inflammation. Inflamm Res. 2008; 57(10):450–6. doi: 10.1007/s00011-008-7222-7 PMID:18827967.

68. Nilistino-Souza R, Rodrigues-Lisoni FC, Cury PM, Maniglia JV, Raposo LS, Tajara EH, et al. Annexin 1: differential expression in tumor and mast cells in human larynx cancer. Int J Cancer. 2007; 120(12):2582–9. doi: 10.1002/ijc.22639 PMID:17340616.

69. Markoff A, Gerke V. Expression and functions of annexins in the kidney. Am J Physiol Renal Physiol. 2005; 289(5):F949–56. Epub 2005/10/08. doi: 289/5/F949 [pii] doi:10.1152/ajprenal.00089.2005 PMID:16210453.

70. Chutipongtanate S, Fong-ngem K, Peerapen, Thongboonkerd V. High calcium enhances calcium oxalate crystal binding capacity of renal tubular cells via increased surface annexin A1 but impairs their proliferation and healing. J Proteome Res. 2012; 11(7):3650–63. Epub 2012/05/30. doi: 10.1021/pr3000738 PMID:22640262.